Logo image of ZVRA

ZEVRA THERAPEUTICS INC (ZVRA) Stock Price, Quote, News and Overview

NASDAQ:ZVRA - Nasdaq - US4884452065 - Common Stock - Currency: USD

8.33  -0.12 (-1.42%)

After market: 8.33 0 (0%)

ZVRA Quote, Performance and Key Statistics

ZEVRA THERAPEUTICS INC

NASDAQ:ZVRA (5/28/2025, 8:10:02 PM)

After market: 8.33 0 (0%)

8.33

-0.12 (-1.42%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High9.76
52 Week Low4.2
Market Cap455.48M
Shares54.68M
Float53.25M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE14
Earnings (Next)08-11 2025-08-11/bmo
IPO04-16 2015-04-16


ZVRA short term performance overview.The bars show the price performance of ZVRA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10 15

ZVRA long term performance overview.The bars show the price performance of ZVRA in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of ZVRA is 8.33 USD. In the past month the price increased by 15.21%. In the past year, price increased by 79.14%.

ZEVRA THERAPEUTICS INC / ZVRA Daily stock chart

ZVRA Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 52.28 681.79B
JNJ JOHNSON & JOHNSON 15.17 366.76B
NVO NOVO-NORDISK A/S-SPONS ADR 19.22 304.82B
NVS NOVARTIS AG-SPONSORED ADR 13.46 220.95B
AZN ASTRAZENECA PLC-SPONS ADR 16 218.21B
MRK MERCK & CO. INC. 9.78 191.27B
PFE PFIZER INC 7.22 131.79B
SNY SANOFI-ADR 11.79 126.53B
BMY BRISTOL-MYERS SQUIBB CO 6.4 95.59B
GSK GSK PLC-SPON ADR 8.84 79.50B
ZTS ZOETIS INC 27.48 73.64B
HLN HALEON PLC-ADR 22.96 50.66B

About ZVRA

Company Profile

ZVRA logo image Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The company is headquartered in Celebration, Florida and currently employs 59 full-time employees. The company went IPO on 2015-04-16. The company has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Company Info

ZEVRA THERAPEUTICS INC

1180 Celebration Boulevard, Suite 103

Celebration FLORIDA US

Employees: 59

ZVRA Company Website

ZVRA Investor Relations

Phone: 13219393416

ZEVRA THERAPEUTICS INC / ZVRA FAQ

What is the stock price of ZEVRA THERAPEUTICS INC today?

The current stock price of ZVRA is 8.33 USD. The price decreased by -1.42% in the last trading session.


What is the ticker symbol for ZEVRA THERAPEUTICS INC stock?

The exchange symbol of ZEVRA THERAPEUTICS INC is ZVRA and it is listed on the Nasdaq exchange.


On which exchange is ZVRA stock listed?

ZVRA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ZEVRA THERAPEUTICS INC stock?

14 analysts have analysed ZVRA and the average price target is 22.73 USD. This implies a price increase of 172.89% is expected in the next year compared to the current price of 8.33. Check the ZEVRA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ZEVRA THERAPEUTICS INC worth?

ZEVRA THERAPEUTICS INC (ZVRA) has a market capitalization of 455.48M USD. This makes ZVRA a Small Cap stock.


How many employees does ZEVRA THERAPEUTICS INC have?

ZEVRA THERAPEUTICS INC (ZVRA) currently has 59 employees.


What are the support and resistance levels for ZEVRA THERAPEUTICS INC (ZVRA) stock?

ZEVRA THERAPEUTICS INC (ZVRA) has a support level at 8.32 and a resistance level at 8.54. Check the full technical report for a detailed analysis of ZVRA support and resistance levels.


Is ZEVRA THERAPEUTICS INC (ZVRA) expected to grow?

The Revenue of ZEVRA THERAPEUTICS INC (ZVRA) is expected to grow by 325.15% in the next year. Check the estimates tab for more information on the ZVRA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ZEVRA THERAPEUTICS INC (ZVRA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ZEVRA THERAPEUTICS INC (ZVRA) stock pay dividends?

ZVRA does not pay a dividend.


When does ZEVRA THERAPEUTICS INC (ZVRA) report earnings?

ZEVRA THERAPEUTICS INC (ZVRA) will report earnings on 2025-08-11, before the market open.


What is the Price/Earnings (PE) ratio of ZEVRA THERAPEUTICS INC (ZVRA)?

ZEVRA THERAPEUTICS INC (ZVRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.92).


What is the Short Interest ratio of ZEVRA THERAPEUTICS INC (ZVRA) stock?

The outstanding short interest for ZEVRA THERAPEUTICS INC (ZVRA) is 10.42% of its float. Check the ownership tab for more information on the ZVRA short interest.


ZVRA Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to ZVRA. When comparing the yearly performance of all stocks, ZVRA is one of the better performing stocks in the market, outperforming 94.28% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ZVRA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ZVRA. ZVRA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ZVRA Financial Highlights

Over the last trailing twelve months ZVRA reported a non-GAAP Earnings per Share(EPS) of -1.92. The EPS decreased by -42.22% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -53.26%
ROE -224.24%
Debt/Equity 1.46
Chartmill High Growth Momentum
EPS Q2Q%85%
Sales Q2Q%495.65%
EPS 1Y (TTM)-42.22%
Revenue 1Y (TTM)44.9%

ZVRA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to ZVRA. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of 129.85% and a revenue growth 325.15% for ZVRA


Ownership
Inst Owners62.6%
Ins Owners6.34%
Short Float %10.42%
Short Ratio11.24
Analysts
Analysts84.29
Price Target22.73 (172.87%)
EPS Next Y129.85%
Revenue Next Year325.15%